MONTGOMERY COUNTY, Md. (WDVM) – BioNTech has announced that it will soon join Montgomery County’s growing list of world-class international companies in the “Immunology Capital Beside the Nation’s Capital.”
The Germany-based company acquires a manufacturing plant and a cell therapy R&D platform from Kite. The company worked with Pfizer on the widely distributed COVID-19 vaccine. In this new facility, BioNTech seeks to increase its production of cell therapy to support more clinical trials in cancer.
Benjamin H. Wu, President and CEO of Montgomery County Economic Development Corporation (MCDED), Says Decision Signals The County’s Growing Maturation As A Global Immunology
“To see Montgomery County businesses helping to develop these remedies and treatments, but also more recently to be able to see how they help support COVID-19 vaccines and bring us a sense of normalcy… it brings us a lot of pride,”, Wu said.
The BioNTech and Kite transaction is expected to be finalized by the end of July 2021.